It has been shown that angiotensin (ANG)-(1-7) activates nitric oxide synthase (NOS) in isolated ventricular myocytes from normotensive rats. Since many ANG-(1-7) actions are enhanced in situations of increased ANG II activity, as in hypertension, in this study we investigated the in vivo effect of ANG-(1-7) on NOS activity and expression of endothelial (eNOS), neuronal (nNOS), and inducible NOS (iNOS) in ventricles from spontaneously hypertensive rats (SHR). Rats were subjected to a 60-min ANG-(1-7) infusion (0.35 nmol/min); controls received saline. NOS activity was measured using the NADPH diaphorase histochemical method and by the conversion of L-[
receptor Mas has been shown to bind ANG-(1-7) and is involved in many of its biological actions (30, 35) .
The renin-angiotensin system is involved in the development of hypertension, cardiac hypertrophy, and subsequent transition to heart failure (20, 29) . In contrast to ANG II, which causes unfavorable cardiac remodeling leading to reduced cardiac performance and an increased risk of cardiac events, ANG-(1-7) exhibits cardioprotective effects (17, 30, 35) . For instance, ANG-(1-7) decreases the incidence and duration of reperfusion arrhythmias, preserves cardiac function, coronary perfusion, and aortic endothelial function in a rat model of heart failure, protects against pressure overload-induced cardiac hypertrophy and interstitial fibrosis, and causes a decrease in myocyte growth (17, 30, 35) . In addition, a transgenic model with ANG-(1-7) overexpression showed a reduction in cardiac hypertrophy and shorter duration of reperfusion arrhythmias, as well as improved postischemic function (3) .
ANG-(1-7) elicits beneficial effects not only by itself but also by blockade of ANG II cardiac deleterious action. For instance, ANG II infusion resulted in an increased myocyte hypertrophy and myocardial fibrosis, and this ANG II-induced cardiac remodeling was attenuated by coinfusion with ANG-(1-7) (12) . Altogether these results clearly show that ANG-(1-7) exerts a cardioprotective role.
Many actions elicited by ANG-(1-7) are mediated by nitric oxide (NO) (17, 30, 35) . NO is synthesized from L-arginine by a family of NAD(P)H-dependent nitric oxide synthases (NOS): two constitutively expressed enzymes, neuronal (nNOS) and endothelial NOS (eNOS), and a cytokine-inducible isoform (iNOS) (31, 33) . NO generated within the heart has long been known to influence myocardial function (31, 33) . Paracrine and autocrine regulation of cardiomyocyte function by NO is dependent on the distinct subcellular locations of nNOS and eNOS (23, 31, 33) .
It has been shown that ANG-(1-7) via Mas receptors activates eNOS, leading to NO production in isolated ventricular myocytes from normotensive mice (7) . Since many ANG-(1-7) actions are enhanced in situations of ANG II increased activity, such as in hypertension (9) , in this study we investigated the in vivo effect of ANG-(1-7) on NOS activity and in the expression of eNOS, nNOS, and iNOS in ventricles from SHR. In addition, the mechanism of action of ANG-(1-7) on NOS activity was also evaluated.
MATERIALS AND METHODS

Materials. L-[
14 C]arginine (specific activity: 13.32 GBq/mmol, 360 mCi/mmol) was purchased from PerkinElmer Life and Analytical Sciences (Boston MA). PD-123319 was a gift from Dr. Jack Hodges (Parke Davis, Detroit, MI). ANG-(1-7) and [D-Ala 7 ]-ANG-(1-7) were synthesized in our laboratory using the Merrifield solid-phase procedure, as previously described (22) . The crude peptide was purified and characterized as a single component by high-performance liquid chromatography. It showed the correct amino acid composition and sequence. Peptide purity (Ͼ97%) was confirmed by matrixassisted laser desorption mass spectrometry. All other chemicals were analytical grade reagents of the highest purity available.
Animals. Three-month-old male SHR were used in our study. The study was approved by the Animals Studies Committee of the School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 1996) .
In vivo effect of ANG-(1-7) on NOS activity and expression. ANG-(1-7) infusion was performed as previously described (5) . Briefly, rats were anesthetized with urethane (1g/kg body wt ip), and catheters were inserted into the right carotid artery and right jugular vein for direct mean arterial pressure (MAP) measurement and drug administration, respectively. MAP was measured with a Statham P23 ID pressure transducer (Gould Instruments, Cleveland, OH) and recorded with a polygraph (Physiograph E & M, Houston, TX). Data were obtained using a data acquisition program (Labtech Notebook; Laboratory Technologies, Wilmington, MA). After a 60-min period of infusion with saline (0.05 ml/min) for MAP stabilization, rats were administered ANG-(1-7) in a bolus injection (10 nmol/0.1 ml; 30 nmol/kg) followed by a 60-min infusion (0.35 nmol/min). Controls received saline. MAP was registered from the injection and during the entire 60-min infusion. In another group of SHR, nitro-L-arginine methyl ester (L-NAME, a NOS inhibitor) was subcutaneously injected (3 mg/kg) 1 h before ANG-(1-7). The L-NAME dose used in this protocol has been shown to induce no changes in MAP (40) .
NOS activity was measured in left ventricles from saline-or ANG-(1-7)-infused rats by using the NADPH diaphorase histochemical method as described previously (37) . It was also evaluated by the conversion of L-[
14 C]arginine to citrulline (14) . Briefly, left ventricles from saline-or ANG-(1-7)-infused rats were homogenized in ice-cold 50 mM Tris·HCl buffer (pH 7.4) containing 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 M leupeptin, and 0.32 M sucrose. The homogenates were centrifuged at 20,000 g for 30 min at 4°C. NOS activity was evaluated in the supernatant by the conversion of L-[ 14 C]arginine to citrulline as previously described (14) . In preliminary experiments, NOS activity was measured in the absence or presence of either calcium chloride or NADPH. No NOS activity was detected in the absence of these cofactors, ruling out iNOS activity (data not shown). NOS activity was also measured in the presence of a NOS inhibitor (L-NAME), and no activity was detected (data not shown). Therefore, in the present study, the NOS activity reflects a combined activity of eNOS and nNOS. Results are expressed as picomoles of [ 14 C]citrulline per gram of tissue per minute. NOS expression and eNOS phosphorylation were determined by Western blot analysis. Briefly, left ventricles from saline-or ANG-(1-7)-infused rats were homogenized in ice-cold buffer (pH 7.4) containing 50 mM Tris, 10 mM EDTA, 150 mM NaCl, 1% Triton X-100, 1 mM PMSF, 10 g/ml aprotinin, and 2 g/ml leupeptin. Homogenates were centrifuged at 12,000 g for 30 min at 4°C, and supernatants were used for Western blotting. Equal amounts of protein were subjected to 7.5% SDS-PAGE and transferred electrophoretically to polyvinylidene difluoride membrane. Nonspecific binding sites on the membrane were blocked by incubation with 5% milk in Tris-buffered saline solution containing 0.1% Tween 20. Membranes were subsequently probed with mouse anti-eNOS (1:750; BD Transduction Laboratories, Franklin Lakes, NJ), mouse anti-nNOS (1:750; BD Transduction Laboratories), mouse anti-iNOS (1:750; BD Transduction Laboratories), or rabbit anti-phospho-eNOS Ser 1177 (Santa Cruz Biotechnology, Santa Cruz, CA), followed by incubation with goat anti-species IgGs coupled to horseradish peroxidase (Amersham Biosciences, Piscataway, NJ). Immunoreactive bands were visualized by chemiluminescence detection (ECL Plus reagent; Amersham Biosciences) and quantified by densitometry. Protein loading in gels was evaluated by reblotting membranes with anti-␤-actin antibody (1: 1,000). NOS contents relative to ␤-actin are expressed as the percentage of change with respect to basal conditions, with basal taken as 100%. eNOS phosphorylation at Ser 1177 was normalized to eNOS content in the same sample and expressed as a percentage of change with respect to basal conditions, with basal taken as 100%.
In vitro effect of ANG-(1-7) on NOS enzymatic activity. Slices from left ventricles from 3-mo-old male SHR, preincubated in Krebs solution in the absence or presence of ANG-(1-7) for 15 min, were homogenized in ice-cold 50 mM Tris·HCL buffer (pH 7.4) containing 1 mM PMSF, 1 M leupeptin, and 0.32 M sucrose. The homogenates were centrifuged at 20,000 g for 30 min at 4°C. NOS activity was evaluated in the supernatant by the conversion of L-[
14 C]arginine to citrulline as described above.
In vitro effect of ANG-(1-7) on eNOS phosphorylation. Slices from left ventricles from 3-mo-old male SHR, preincubated in Krebs solution in the absence or presence of 100 nM ANG-(1-7) for 10, 20, and 30 min, were homogenized and subjected to Western blot analysis as described above.
Statistics. Data are means Ϯ SE. Statistical significance was assessed using one-way analysis of variance (ANOVA) followed by the Bonferroni post test or Student's t-test (GraphPad Prism 4; GraphPad Software). P values Ͻ0.05 were considered significant. Figure 1 shows the effect of ANG-(1-7) infusion in SHR. ANG-(1-7) infusion caused a significant decrease in MAP, and this effect was blocked when ANG-(1-7) was coinfused with the NOS inhibitor L-NAME.
RESULTS
ANG-(1-7) infusion upregulates NOS activity, phosphorylation, and expression.
When SHR rats were infused with ANG-(1-7), NADPH diaphorase activity in the left ventricle increased. This effect was not observed when NO generation was blocked by L-NAME (Fig. 2) . Fig. 1 . Effect of angiotensin (ANG)-(1-7) infusion on mean arterial pressure (MAP) in spontaneously hypertensive rats (SHR). Rats were given saline or a bolus injection of ANG-(1-7) (10 nmol/0.1 ml) plus a 60-min saline or ANG-(1-7) (0.35 nmol/min) infusion. In another group of SHR, nitro-Larginine methyl ester (L-NAME) was subcutaneously injected (3 mg/kg) 1 h before ANG-(1-7). Values are means Ϯ SE (n ϭ 7 rats in each group). *P Ͻ 0.05 vs. saline-infused SHR.
NOS activity was also evaluated by the conversion of L-arginine to L-citrulline. As shown in Fig. 3A , ANG-(1-7) infusion caused an increase in NOS activity. eNOS activity is regulated by various kinases (24) . Phosphorylation of eNOS at Ser 1177 close to the carboxy terminus is a critical requirement for eNOS activation. The role of ANG-(1-7) in eNOS activation was evaluated by measuring eNOS phosphorylation at Ser 1177 . As shown in Fig. 3B , ANG-(1-7) infusion significantly increased Ser 1177 phosphorylation. We evaluated whether ANG-(1-7) infusion induces changes in NOS expression. ANG-(1-7) caused an increase in eNOS and nNOS expression of 67.4 Ϯ 6.4 and 51 Ϯ 10%, respectively. In contrast, iNOS expression was not modified by ANG-(1-7) infusion (Fig. 4) .
ANG-(1-7)-stimulated NOS activity is coupled to AT 2 activation through a bradykinin (BK)-dependent mechanism.
To further characterize the mechanism by which ANG-(1-7) modifies NOS activity and to avoid hemodynamics influences, we determined the effect of the peptide on NOS activity in vitro in isolated ventricular slices. When ventricles isolated from SHR were incubated with ANG- (1-7) , an increase in NOS activity was observed (Fig. 5) .
The action of ANG-(1-7) on NOS enzymatic activity was modified by neither 1 M [D-Ala 7 ]-ANG- (1-7) , the Mas receptor antagonist, nor 1 M losartan, the AT 1 receptor antagonist. In contrast, 1 M PD-123319, an AT 2 receptor antagonist, blocked the effect of 100 nM ANG-(1-7), suggesting the involvement of AT 2 receptors (Fig. 6 ). The antagonists alone did not modify NOS activity (data not shown). It has been demonstrated that AT 2 receptor activation is coupled to BK generation, which in turn leads to NOS activation through B 2 receptor stimulation (1, 21, 36 ). To test whether this mechanism is involved in the ANG-(1-7)-stimulated NOS activity, we assayed the effect of the peptide in the presence of the B 2 receptor antagonist icatibant. The B 2 receptor antagonist (1 M) completely blocked the increase in NOS enzymatic activity induced by 100 nM ANG-(1-7) (Fig. 7) .
In addition, 100 nM ANG-(1-7) significantly increased eNOS phosphorylation at Ser 1177 with significant effects occurring within 10 min of stimulation (Fig. 8A) . Immunoblotting of lysates with a nonphosphospecific eNOS antibody confirmed that changes in phosphorylation were not caused by changes in the total amount of eNOS protein. The ANG-(1-7)-stimulated eNOS phosphorylation was not modified by the Mas receptor antagonist, but it was completely blunted by either the AT 2 or the B 2 receptor antagonist, reinforcing the concept that ANG-(1-7) enhances NOS activity by an AT 2 -and BK-dependent manner (Fig. 8B) . ANG-(1-7) . eNOS phosphorylation at Ser 1177 was measured by Western blotting as described in MATERIALS AND METHODS. Bar graph values are means Ϯ SE (n ϭ 6 rats in each group). *P Ͻ 0.05 compared with basal.
DISCUSSION
Our present work shows for the first time the in vivo effect of ANG-(1-7) on cardiac NOS activity and expression in a model of essential hypertension. We have shown that ANG-(1-7) caused a decrease in MAP in SHR, accompanied by an increase in cardiac NOS enzymatic activity, phosphorylation, and expression. The stimulatory effect of ANG-(1-7) on NOS activity and phosphorylation is coupled to AT 2 activation through a BK-dependent mechanism.
In agreement with our present results demonstrating a depressor action of ANG-(1-7) in SHR, it has been previously demonstrated that chronic infusion of ANG-(1-7) caused a decrease in MAP in SHR (2) and that ANG-(1-7) given acutely evoked a depressor response in SHR that is observed in the presence of the AT 1 receptor antagonist (38) . Intrahypothalamic injections of ANG-(1-7) blocked the pressor response caused by intrahypothalamic ANG II administration in SHR (16) . Together, these results suggest that ANG-(1-7) contributes to lowering of blood pressure in situations of increased ANG II activity such as in hypertension.
In addition, the depressor action of ANG-(1-7) in SHR may be the result of an increase in NOS activity, since it was blocked in the presence of a NOS inhibitor (Fig. 1) . In fact, we showed that in vivo ANG-(1-7) stimulated cardiac NOS activity, eNOS phosphorylation at Ser 1177 , and eNOS and nNOS expression in SHR. eNOS and nNOS isoforms subserve dis- Fig. 4 . eNOS, neuronal (nNOS), and inducible NOS (iNOS) expression in ventricles from SHR infused with saline (basal) or ANG-(1-7). NOS expression was measured by Western blotting as described in MATERIALS AND METHODS and is expressed as a percentage of the response detected in basal conditions, i.e., rats infused with saline alone. Each bar represents the mean Ϯ SE (n ϭ 6 -8 rats in each group). *P Ͻ 0.05 compared with basal. A representative Western blot reflecting the media results presented in each bar graph is shown in which the replicate bands were cut. 1-7) on NOS enzymatic activity in ventricles isolated from SHR. Ventricles from SHR were preincubated in the absence (control) or presence of 10 nM, 100 nM, or 1 M ANG-(1-7) for 15 min, and NOS activity was determined as described in MATERIALS AND METHODS. Values are means Ϯ SE (n ϭ 8 rats in each group). *P Ͻ 0.05 compared with control. tinct functions in the myocardium as a consequence of their different subcellular localization, regulation, and coupling to downstream targets (23, 31, 33) . In pathophysiological situations, other than the level of total NOS activity, unique changes in NO compartmentation secondary to eNOS or nNOS subcellular location might be involved in the development of cardiac hypertrophy and failure (6, 31, 33) . Thus the upregulation of NOS activity and expression induced by ANG-(1-7) infusion could account for the cardiac effects and antigrowth actions elicited by the peptide.
Several studies have shown that ANG-(1-7) effects are enhanced in situations of increased ANG II activity, such as in hypertension, thus counterbalancing ANG II pressor and proliferative actions (9, 30 ). Thus our study shows that ANG-(1-7) may increase NO production not only through NOS stimulation, counterbalancing in this way the pressor and trophic actions of ANG II, but also by increasing NO bioavailability. Increased reactive oxygen species in SHR have been demonstrated to enhance NO inactivation and reduce NO bioavailability (31, 33) , which contributes to the maintenance of hypertension.
The fact that ANG-(1-7) induces an increase in cardiac NOS expression (present results) may be due to a posttranslational effect. NOS enzymes are regulated, in part, by posttranslational proteolysis (28) . The ubiquitin-proteasome system (UPS) represents the major pathway for intracellular protein degradation in eukaryotic cells (11) . Recent reports have identified the UPS as the primary degradation pathway for iNOS, nNOS, and eNOS (25, 34) . Thus we could not disregard the possibility that the ANG-(1-7)-induced increase in NOS expression may be a posttranslational effect via inhibition of the proteasome activity. In fact, ANG-(1-7) acting through the UPS induces changes in neuronal tyrosine hydroxylase expression in neuronal cultures from SHR (22) . Further experiments should be done to test this hypothesis.
Regulation of eNOS activity involves multisite phosphorylation of specific serine and threonine residues (24) . Phosphorylation of eNOS-Ser 1177 close to the carboxy terminus is a critical requirement for eNOS activation (24) . Although studies in endothelial cells demonstrate that numerous kinases and phosphatases contribute to the regulation of eNOS activity, thus far cardiac studies have been restricted in their focus to the relationship between the phosphatidylinositol 3-kinase (PI3K)/ Akt pathway and eNOS phosphorylation. It has been reported in heart and endothelial cells that BK leads to a PI3K-dependent increase in the phosphorylation of eNOS at Ser 1177 (13, 19) . In addition, ANG-(1-7), through Mas, stimulates eNOS activation and NO production via PI3K/Akt-dependent pathways in human aortic endothelial cells (27) . Our present work shows that in left ventricles from SHR, ANG-(1-7) increased eNOS phosphorylation at Ser 1177 , which may lead to eNOS ]-ANG-(1-7) (1 M), or Krebs buffer alone (control) and then incubated for a further 10 min with 100 nM ANG-(1-7). eNOS phosphorylation was determined by Western blotting as described in MATERIALS AND METHODS. Values are means Ϯ SE (n ϭ 6 rats in each group). *P Ͻ 0.05 compared with basal. A representative Western blot reflecting the media results presented in the bar graph is shown in which the replicate bands were cut. Because different samples of the same treatment were loaded in the same gel and not enough wells were available for all the different treatments, the representative Western blot is a composite of different gels. activation. Since the ANG-(1-7)-stimulated eNOS phosphorylation was blocked by the B 2 receptor and not by Mas receptor antagonist, our results suggest that ANG-(1-7) induces eNOS phosphorylation through a BK-dependent mechanism.
In addition, our present work shows that in SHR, the ANG-(1-7)-stimulated NOS activity is coupled to AT 2 receptor activation. In accord, ANG-(1-7) was reported to cause stimulation of NO release from bovine aortic endothelial cells, and this effect was attenuated by up to 90% with an AT 2 receptor antagonist, demonstrating that ANG-(1-7) increases NO generation through AT 2 receptors stimulation (15) . On the other hand, Seyedi et al. (32) have shown that ANG-(1-7) increased nitrite release in isolated coronary microvessels and large coronary arteries from the normal dog heart through AT 1 and AT 2 receptor stimulation. Thus different reports demonstrate a stimulatory effect of ANG-(1-7) on NO generation, but the type of receptor involved depends on the tissue or the physiopathological situation.
Several data suggest that some of the cardiac actions of ANG-(1-7) are mediated by Mas receptors (17, 30) , although AT 1 or AT 2 blockade have not been tested. Through AT 2 receptor activation, ANG-(1-7) caused an increase in NOS activity (present results), and these mechanisms may be involved in its cardioprotective action. In fact, it has been shown that AT 2 receptors elicit cardioprotective effects. For instance, AT 2 receptor overexpression in the mouse heart preserves left ventricular structure and function after myocardial infarction, and the cardiac NO pathway is involved in this beneficial effect (4). In addition, AT 2 receptor overexpression caused a decreased hypertrophy, fibrosis, and left ventricular wall thickness in an ANG II-infused rat model of hypertension (8) . Additionally, AT 2 null mice have greater cardiac remodeling/ hypertrophy, systolic and diastolic dysfunction, and increased mortality after myocardial infarction compared with wild-type mice (26) , reinforcing the concept that AT 2 receptors elicit cardioprotection. In contrast, Xu et al. (39) have demonstrated that AT 2 receptors do not play an essential role in regulation of cardiac function and morphology, either under normal conditions or during the development of heart failure. However, activation of AT 2 plays a significant role in the therapeutic effect of AT 1 receptor antagonists (18, 39) .
It has been demonstrated that AT 2 receptor activation induces BK generation, which in turn stimulates B 2 receptors, leading to NOS activation (1, 21, 36) . In addition, formation of NO from coronary microvessels and large arteries in the normal dog heart in response to ANG-(1-7) is due to the activation of local kinin production, and this effect is coupled to AT 2 receptor activation (32) . Accordingly, the stimulatory effect of ANG-(1-7) on NOS activity in ventricles from SHR is blocked by both B 2 receptor and AT 2 receptor antagonists (present results), suggesting that an AT 2 /BK mechanism plays a critical role in the increase in NOS activity caused by ANG- (1-7) . Concerning the mode of interaction between AT 2 and B 2 receptors, a heterodimer between AT 2 and B 2 receptors has been demonstrated to be responsible for the enhanced NO generation, and this requires AT 2 receptor activation (1). Thus we can speculate that ANG-(1-7) may bind to AT 2 receptors with its subsequent activation, which leads to AT 2 -B 2 receptor heterodimerization, leading to NOS activation.
In conclusion, the present study demonstrates that ANG-(1-7) infusion is accompanied by an increase in NOS activity, eNOS phosphorylation, and eNOS and nNOS expression in SHR. The stimulatory effect of ANG-(1-7) on NOS activity and phosphorylation is mediated by the AT 2 receptors in a BK-dependent manner, which in turn causes NOS activation. In this way ANG-(1-7) may elicit its cardioprotective action and contribute to some of the counterregulatory AT 2 receptor effects that oppose the AT 1 receptor-mediated effects.
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